Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Saturday, Assembly Biosciences Presents Phase 1a And Preclinical Data For ABI-5366 And ABI-1179 Herpes Candidates At STI & HIV 2025 And International Herpesvirus Workshop

Author: Benzinga Newsdesk | July 28, 2025 01:23am

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

– Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted –

– Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 –

Posted In: ASMB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist